Investor science conference call from ESMO 2014

Madrid, 29 September 2014
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others:

1. Pricing and product initiatives of competitors;
2. Legislative and regulatory developments and economic conditions;
3. Delay or inability in obtaining regulatory approvals or bringing products to market;
4. Fluctuations in currency exchange rates and general financial market conditions;
5. Uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products;
6. Increased government pricing pressures;
7. Interruptions in production;
8. Loss of or inability to obtain adequate protection for intellectual property rights;
9. Litigation;
10. Loss of key executives or other employees; and
11. Adverse publicity and news coverage.

Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche.

For marketed products discussed in this presentation, please see full prescribing information on our website – [www.roche.com](http://www.roche.com)

All mentioned trademarks are legally protected.
Introduction

*Karl Mahler, Head of Investor Relations, Roche*
Agenda

Introduction
Dr. Karl Mahler, Head of Investor Relations

Update on key oncology data
Stefan Frings MD, Medical Director, Roche Germany

Breast cancer
- Avastin in 1st line maintenance and treatment through multiple lines HER2-neg. mBC: phase III IMELDA and TANIA
- Perjeta in 1st line HER2-pos. mBC: final overall survival data phase III CLEOPATRA

Metastatic melanoma
- Combination of cobimetinib and Zelboraf in BRAF-mutated metastatic melanoma frontline setting: phase III coBRIM

Update on cancer immunotherapy
Cathi Ahearn, Lifecycle Leader anti-PDL1, Genentech

MPDL3280A (anti-PDL1) in solid tumors
- Phase I combination with Avastin +/-chemo, monotherapy RCC, update bladder cancer
Breast cancer: Still high unmet medical need
Roche proposing solutions for most segments

ER+/PR+/Her2+ 11%
ER-/PR+/Her2+ 10%
ER+/PR-/Her2+ 7%
ER-/PR-/Her2+ 13%
ER+/PR-/Her2- 1%
ER-/PR+/Her2- 55%

Taselisib
PI3K inhibitor

Pictilisib
PI3K inhibitor
Continuing to raise the efficacy bar in HER2-positive metastatic breast cancer

- illustrative. MARIANNE trial ongoing, results are not yet available.
Continuing to raise the efficacy bar in metastatic melanoma

Cobimetinib+Zelboraf combo: filed in Europe and fast-track designation in US; FDA filing expected Q4 2014

* ipilimumab pre-treated patients
**BRAF-mutation positive patients
Roche in cancer immunotherapy
A comprehensive program

<table>
<thead>
<tr>
<th>Compound</th>
<th>Indication</th>
<th>Phase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PDL1</strong></td>
<td>Lung: mono/combo</td>
<td>☑</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td><strong>PDL1</strong></td>
<td>Bladder</td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td><strong>PDL1</strong></td>
<td>Renal: mono/combo</td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PDL1</strong></td>
<td>Melanoma</td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PDL1</strong></td>
<td>Other solid tumors: mono/combo</td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PDL1</strong></td>
<td>CRC</td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>PDL1</strong></td>
<td>Hematology/combo</td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CSF1R</strong></td>
<td>Solid tumours/PVNS</td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td>☑️</td>
</tr>
<tr>
<td><strong>CEA IL-2v</strong></td>
<td>Solid tumours</td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ox 40</strong></td>
<td>Solid tumours</td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>CD40</strong></td>
<td>Solid tumours</td>
<td>☑️</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INO</strong></td>
<td>Solid tumours</td>
<td>☑️</td>
</tr>
</tbody>
</table>

☑️ Study ongoing  ☑️ Study planned
## PDL1 in bladder: A strong set of data

**ASCO 2014: N= 65**  
Mai /June 2014

<table>
<thead>
<tr>
<th>PD-L1 IHC (n)</th>
<th>ORR (95% CI)</th>
<th>Dx+ vs Dx- ORR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHC 3 (n=10)</td>
<td>50% (22-78)</td>
<td>43% (26-63)</td>
</tr>
<tr>
<td>IHC 2 (n=20)</td>
<td>40% (22-64)</td>
<td></td>
</tr>
<tr>
<td>IHC 1 (n=23)</td>
<td>13% (4-32)</td>
<td>11% (4-26)</td>
</tr>
<tr>
<td>IHC 0 (n=12)</td>
<td>8% (0.4-35)</td>
<td></td>
</tr>
</tbody>
</table>

**ESMO 2014: N=70**  
September 2014

<table>
<thead>
<tr>
<th>PD-L1 IHC (n)</th>
<th>ORR (95% CI)</th>
<th>Dx+ vs Dx- ORR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHC 3 (n=10)</td>
<td>60% (27-85)</td>
<td>52% (34-69)</td>
</tr>
<tr>
<td>IHC 2 (n=23)</td>
<td>48% (27-68)</td>
<td></td>
</tr>
<tr>
<td>IHC 1 (n=24)</td>
<td>17% (6-37)</td>
<td>14% (6-28)</td>
</tr>
<tr>
<td>IHC 0 (n=12)</td>
<td>8% (0-35)</td>
<td></td>
</tr>
</tbody>
</table>

- After 6 weeks follow-up
- 2 complete responses in PD-L1+
- 16/17 responders continuing to respond

- Median of 6 months follow-up
- 3 complete responses in PD-L1+
- 19/22 responders continuing to respond

*1 pt has unknown IHC (IC) status
Update on key oncology data

Stefan Frings MD, Medical Director, Roche Germany
Agenda

Update on key oncology data

Breast cancer
Avastin in 1st line maintenance and treatment through multiple lines HER2-neg. mBC: phase 3 IMELDA and TANIA

Perjeta in 1st line HER2-pos. mBC: final overall survival data phase 3 CLEOPATRA

Melanoma
Cobimetinib + Zelboraf in metastatic BRAF-mutated melanoma frontline setting: phase 3 coBRIM
IMELDA: Open-label randomised phase III trial

### Stratification factors
- ER status (positive vs negative), visceral metastasis (present vs absent), stable disease/response/non-measurable disease, LDH concentration ($\leq 1.5$ vs $>1.5 \times$ ULN)

### Primary endpoint (maintenance population)
- PFS from the time of randomisation to progression/death

### Key secondary endpoints
- Overall response rate (ORR), clinical benefit rate, time to disease progression, overall survival (OS)

---

BEV = bevacizumab; CAP = capecitabine; CR = complete response; DOC = docetaxel; ER = oestrogen receptor; LDH = lactate dehydrogenase; LR/mBC = locally recurrent/metastatic breast cancer; PD = progressive disease; PR = partial response; SD = stable disease; R = randomisation; ULN = upper limit of normal.

* Avastin is licenced by EMA for 1L therapy of metastatic Breast Cancer combination with paclitaxel or capecitabine, but not in combination with Docetaxel.
Primary endpoint: PFS from time of randomisation

Estimated probability

Time from randomisation (months)

Events, n (%)

BEV (N=94)  
83 (88)

BEV–CAP (N=91)  
69 (76)

Median PFS, months

4.3

11.9

Stratified hazard ratio

(95% CI)

0.38

(0.27–0.55)

Stratified 2-sided log-rank test

p<0.001

Stratification factors: ER status, visceral metastasis, stable disease/response/non-measurable disease, LDH concentration
Secondary endpoint: OS from time of randomisation

<table>
<thead>
<tr>
<th></th>
<th>BEV (N=94)</th>
<th>BEV–CAP (N=91)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events, n (%)</td>
<td>53 (56)</td>
<td>33 (36)</td>
</tr>
<tr>
<td>1-year OS rate (%)</td>
<td>72</td>
<td>90</td>
</tr>
<tr>
<td>2-year OS rate (%)</td>
<td>49</td>
<td>69</td>
</tr>
<tr>
<td>Stratified hazard ratio</td>
<td><strong>0.43</strong></td>
<td><strong>0.26–0.69</strong></td>
</tr>
<tr>
<td>(95% CI)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stratified 2-sided log-rank</td>
<td>p&lt;0.001</td>
<td></td>
</tr>
</tbody>
</table>

Estimated probability

Time from randomisation (months)

No. at risk

<table>
<thead>
<tr>
<th></th>
<th>BEV–CAP</th>
<th>BEV</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>91</td>
<td>94</td>
</tr>
<tr>
<td>3</td>
<td>87</td>
<td>89</td>
</tr>
<tr>
<td>6</td>
<td>84</td>
<td>84</td>
</tr>
<tr>
<td>9</td>
<td>78</td>
<td>70</td>
</tr>
<tr>
<td>12</td>
<td>72</td>
<td>64</td>
</tr>
<tr>
<td>15</td>
<td>70</td>
<td>59</td>
</tr>
<tr>
<td>18</td>
<td>64</td>
<td>52</td>
</tr>
<tr>
<td>21</td>
<td>60</td>
<td>48</td>
</tr>
<tr>
<td>24</td>
<td>54</td>
<td>41</td>
</tr>
<tr>
<td>27</td>
<td>47</td>
<td>34</td>
</tr>
<tr>
<td>30</td>
<td>43</td>
<td>21</td>
</tr>
<tr>
<td>33</td>
<td>36</td>
<td>12</td>
</tr>
<tr>
<td>36</td>
<td>31</td>
<td>5</td>
</tr>
<tr>
<td>39</td>
<td>29</td>
<td>3</td>
</tr>
<tr>
<td>42</td>
<td>21</td>
<td>1</td>
</tr>
<tr>
<td>45</td>
<td>10</td>
<td>0</td>
</tr>
</tbody>
</table>

23.7
(95% CI: 18.5–31.7)

39.0
(95% CI 32.3–NR)
Most common grade ≥3 AEs (≥2% of patients in either arm)

Patients (%)

- Hand-foot syndrome
- Hypertension
- Proteinuria
- Gastroenteritis
- Asthenia
- Neutropenia
- Thrombocytopenia
- Hypercalcaemia
- Diarrhoea
- Deep vein thrombosis
- GGT increase
- Mucosal inflammation
- Hypokalaemia
- Myocardial infarction
- Irregular menstruation

GGT = gamma glutamyltransferase

BEV (N=92) vs BEV–CAP (N=91)
Conclusions

- Adding CAP to BEV maintenance after initial BEV + taxane demonstrated statistically significant and clinically meaningful improvements in PFS (primary endpoint) and OS
  - Sample size smaller than planned
  - Insufficient duration of follow-up for OS → low event rate for OS (secondary endpoint) especially in the BEV–CAP arm

- No unexpected safety signals
  - Long-term bevacizumab-containing therapy was well tolerated
  - CAP was associated with an increase in hand-foot syndrome (grade 3: 33% vs 0%)

- Ongoing evaluation:
  - Collection of anti-cancer treatment after study therapy
  - Patient-reported outcomes

- In patients benefiting from first-line BEV-containing therapy, continued BEV with oral chemotherapy improves efficacy

* Avastin is licenced by EMA for for 1L therapy of metastatic Breast Cancer combination with paclitaxel or capecitabine but not in combination with Docetaxel.
TANIA: Open-label randomised phase III trial

Stratification factors
• Hormone receptor status, time to first progression (<6 vs ≥6 months), choice of chemotherapy (taxane vs non-taxane vs vinorelbine), LDH concentration (≤1.5 vs >1.5 × UNL)

Primary endpoint
• 2nd-line PFS

Key secondary endpoints
• 2nd-line best overall response rate, 2nd- and 3rd-line PFS, OS, 3rd-line PFS

CT = chemotherapy; LDH = lactate dehydrogenase; nab = nanoparticle albumin-bound; PD = disease progression; R = randomisation; UNL = upper normal limit

*CT options (investigator’s choice, doublets not allowed): paclitaxel, nab-paclitaxel, docetaxel, capecitabine, gemcitabine, pegylated liposomal doxorubicin, non-pegylated liposomal doxorubicin, doxorubicin, epirubicin, vinorelbine, cyclophosphamide, ixabepilone (and in 3rd line only: eribulin)

§ Avastin is licenced by EMA for for 1L therapy of metastatic Breast Cancer until progression of the disease but not for second or third line use nor for use beyond disease progression

Final OS: ≥24 months’ follow-up since randomisation in all patients (or death, withdrawn consent or lost to follow-up)
### Investigator-selected second-line chemotherapy

<table>
<thead>
<tr>
<th>Second-line CT, n (%)</th>
<th>CT (N=238)</th>
<th>CT + BEV (N=245)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Taxane</strong>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paclitaxel</td>
<td>11 (4.6)</td>
<td>16 (6.5)</td>
</tr>
<tr>
<td>Nab-paclitaxel</td>
<td>8 (3.4)</td>
<td>4 (1.6)</td>
</tr>
<tr>
<td>Docetaxel</td>
<td>6 (2.5)</td>
<td>4 (1.6)</td>
</tr>
<tr>
<td>** Anthracycline**</td>
<td>34 (14.3)</td>
<td>36 (14.7)</td>
</tr>
<tr>
<td>Non-pegylated liposomal doxorubicin</td>
<td>20 (8.4)</td>
<td>17 (6.9)</td>
</tr>
<tr>
<td>Pegylated liposomal doxorubicin</td>
<td>8 (3.4)</td>
<td>7 (2.9)</td>
</tr>
<tr>
<td>Doxorubicin</td>
<td>2 (0.8)</td>
<td>7 (2.9)</td>
</tr>
<tr>
<td>Epirubicin</td>
<td>4 (1.7)</td>
<td>5 (2.0)</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>179 (75.2)</td>
<td>184 (75.1)</td>
</tr>
<tr>
<td>Capecitabine</td>
<td>142 (59.7)</td>
<td>148 (60.4)</td>
</tr>
<tr>
<td>Vinorelbine*</td>
<td>26 (10.9)</td>
<td>29 (11.8)</td>
</tr>
<tr>
<td>Gemcitabine</td>
<td>10 (4.2)</td>
<td>5 (2.0)</td>
</tr>
<tr>
<td>Cyclophosphamide</td>
<td>1 (0.4)</td>
<td>2 (0.8)</td>
</tr>
</tbody>
</table>

*Stratification factors: taxane, vinorelbine, the rest (non-taxane)
Primary endpoint: Second-line PFS

Median duration of follow-up: 15.9 months (CT) vs 16.1 months (CT + BEV)

<table>
<thead>
<tr>
<th>Time (months)</th>
<th>0</th>
<th>3</th>
<th>6</th>
<th>9</th>
<th>12</th>
<th>15</th>
<th>18</th>
<th>21</th>
<th>24</th>
<th>27</th>
<th>30</th>
<th>33</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events, n (%)</td>
<td>203 (82)</td>
<td>204 (83)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median PFS, months</td>
<td>4.2</td>
<td>6.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stratified HR (95% CI)</td>
<td>0.75</td>
<td>(0.61–0.93)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Stratified log-rank test</td>
<td>p=0.0068</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

No. at risk

<table>
<thead>
<tr>
<th></th>
<th>CT (N=247)</th>
<th>CT + BEV (N=247)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>203 (82)</td>
<td>204 (83)</td>
</tr>
<tr>
<td>Median PFS, months</td>
<td>4.2</td>
<td>6.3</td>
</tr>
<tr>
<td>Stratified HR (95% CI)</td>
<td>0.75</td>
<td>(0.61–0.93)</td>
</tr>
<tr>
<td>Stratified log-rank test</td>
<td>p=0.0068</td>
<td></td>
</tr>
</tbody>
</table>

Median duration of follow-up: 15.9 months (CT) vs 16.1 months (CT + BEV)
Secondary endpoints: Best response* (second-line treatment from randomisation)

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>CT (N=185)</th>
<th>CT + BEV (N=182)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall response rate, % (95% CI)</td>
<td>16.8 (11.7–22.9)</td>
<td>20.9 (15.2–27.5)</td>
</tr>
<tr>
<td>Difference (95% CI)</td>
<td>4.1 (–4.2 to 12.4)</td>
<td></td>
</tr>
<tr>
<td>Stable disease, %</td>
<td>33.5 (26.8–40.8)</td>
<td>48.9 (41.4–56.4)</td>
</tr>
<tr>
<td>Disease progression, %</td>
<td>41.1 (33.9–48.5)</td>
<td>24.2 (18.1–31.1)</td>
</tr>
<tr>
<td>Duration of response</td>
<td>(N=31)</td>
<td>(N=38)</td>
</tr>
<tr>
<td>Median, months (95% CI)</td>
<td>10.6 (4.4–16.7)</td>
<td>8.3 (6.1–10.3)</td>
</tr>
</tbody>
</table>

*Response Evaluation Criteria in Solid Tumors version 1.0
Most common grade ≥3 AEs (≥3%, second-line safety population)

GGT = gamma glutamyltransferase
Conclusions

• The primary objective of TANIA was met
  – Statistically significant improvement in second-line PFS with further BEV in BEV-pretreated LR/mBC
  – Continuous VEGF suppression appears to be important, consistent with findings in metastatic colorectal cancer

• Effect of second-line BEV on PFS in BEV-pretreated patients (TANIA) appears similar to effect in BEV-naïve patients (RIBBON-2; HR 0.78 [95% CI 0.64–0.93])

• No new safety signals seen; long-term BEV-containing therapy was generally well tolerated

• Biomarker and patient-reported outcomes analyses are ongoing

• Final OS, PFS from randomisation to third-line progression/death and third-line safety results are anticipated in mid 2015

§ Avastin is licenced by EMA for for 1L therapy of metastatic Breast Cancer until progression of the disease but not for second or third line use nor for use beyond disease progression

## Avastin: Standard of care in multiple tumor types with the largest breadth of data

<table>
<thead>
<tr>
<th>Indication</th>
<th>US</th>
<th>EU</th>
<th>New data 2014</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Colorectal</strong></td>
<td>✔</td>
<td>✔</td>
<td>CALGB 80405: Avastin only biologic with proven OS in 1\textsuperscript{st}, 2\textsuperscript{nd} L and TML\textsuperscript{1} irrespective of Ras status</td>
</tr>
<tr>
<td><strong>Lung</strong></td>
<td>✔</td>
<td>✔</td>
<td>JO 25567 in EGFRmut.+ patients: Significant PFS benefit of A+T over Tarceva single agent</td>
</tr>
<tr>
<td><strong>Ovarian</strong></td>
<td>Priority Review</td>
<td>✔</td>
<td>US Priority review in Pt-resistant patients; EU approval, label extension Pt-resistant Aug ’14</td>
</tr>
<tr>
<td><strong>Renal</strong></td>
<td>✔</td>
<td>✔</td>
<td>Promising early data in combination with MPDL3280A (anti-PDL1): ORR 40%</td>
</tr>
<tr>
<td><strong>Brain</strong></td>
<td>✔\textsuperscript{2}</td>
<td>Filed</td>
<td>Negative CHMP opinion Sep ’14</td>
</tr>
<tr>
<td><strong>Breast, HER2-neg</strong></td>
<td>✔</td>
<td></td>
<td>Positive phase 3 data in 1st line maintenance (IMELDA) and 2nd line TML settings (TANIA)</td>
</tr>
<tr>
<td><strong>Cervical</strong></td>
<td>✔</td>
<td>Filed</td>
<td>US approval Aug ’14, based on significant OS benefit of Avastin over chemotherapy</td>
</tr>
</tbody>
</table>

\textsuperscript{1}Treatment through multiple lines of therapy, \textsuperscript{2}Accelerated approval in recurrent GBM; 2012 US sales CHF ~170 m
**Agenda**

*Update on key oncology data*

---

**Breast cancer**

Avastin in 1st line maintenance and treatment through multiple lines HER2-neg. mBC: phase 3 IMELDA and TANIA

Perjeta in 1st line HER2-pos. mBC: final overall survival data phase 3 CLEOPATRA

---

**Melanoma**

Cobimetinib + Zelboraf in metastatic BRAF-mutated melanoma frontline setting: phase 3 coBRIM
**CLEOPATRA Study Design**

**HER2-positive metastatic breast cancer centrally confirmed (N = 808)**

- Stratification factors
  - Geographic region and neo/adjuvant chemotherapy

- **Primary endpoint**
  - Independently assessed PFS at 381 events

- **Secondary endpoints**
  - Investigator-assessed PFS, objective response rate, safety, OS, final analysis planned at 385 deaths, with two interim analyses at 165 and 267 deaths

---

*Placebo + trastuzumab* 8 mg/kg loading → 6 mg/kg maintenance q3w

Docetaxel 75 mg/m² ≥ 6 cycles* q3w

**Pertuzumab** 840 mg loading → 420 mg maintenance + trastuzumab 8 mg/kg loading → 6 mg/kg maintenance q3w

Docetaxel 75 mg/m² ≥ 6 cycles* q3w

---

* < 6 cycles allowed for unacceptable toxicity or PD; > 6 cycles allowed at investigator discretion. Dose escalated to 100mg/m² if tolerated. HER2, human epidermal growth factor receptor 2; PD, progressive disease.

Overall survival 1\textsuperscript{st} interim analysis: May 2011

![Graph showing overall survival with different treatment groups and event-free proportion.](chart)

HR 0.64
p = 0.005
Overall survival 2\textsuperscript{nd} interim analysis: May 2012

* Crossed the prespecified O'Brien-Fleming stopping boundary (HR ≤ 0.739; p ≤ 0.0138)
Overall survival final analysis: Feb 2014

Randomised treatment

Ptz + T + D: median 56.5 months
Pla + T + D: median 40.8 months
Δ 15.7 months
HR 0.68
95% CI = 0.56, 0.84
p = 0.0002

Median follow-up of 50 months (range 0–70 months) at final analysis
Grade $\geq 3$ Adverse Events

*Incidence* $\geq 5\%$

<table>
<thead>
<tr>
<th>Safety population</th>
<th>Placebo + T + D (n = 396), %</th>
<th>Pertuzumab + T + D (n = 408), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neutropenia</td>
<td>46.2</td>
<td>49.0</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>14.9</td>
<td>12.3</td>
</tr>
<tr>
<td>Febrile neutropenia</td>
<td>7.6</td>
<td>13.7</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5.1</td>
<td>9.3</td>
</tr>
</tbody>
</table>

- No cumulative toxicities
CLEOPATRA Conclusions

• First-line treatment with pertuzumab, trastuzumab, and docetaxel significantly improved OS for patients with HER2-positive MBC compared with placebo, trastuzumab, and docetaxel
  – Median OS increased by 15.7 months from 40.8 to 56.5 months
  – Survival benefit consistent across subgroups
  – Investigator-assessed PFS benefit maintained
• No new safety concerns seen with longer follow-up
  – No evidence of cumulative or late toxicity
  – Long-term cardiac safety maintained

The 56.5-month median OS is unprecedented in this indication and confirms the pertuzumab regimen as first-line standard of care for patients with HER2-positive MBC
HER2 franchise update
Improving standard of care in HER2-positive breast cancer in all lines of treatment

- **Early BC**
  - Neoadjuvant BC: Herceptin + chemo (NOAH)\(^1\)
  - Adjuvant BC: Herceptin + chemo

- **1st line mBC**
  - Herceptin + chemo
  - Herceptin & Perjeta + chemo (CLEOPATRA)
  - Herceptin & Perjeta + chemo (APHINITY)

- **2nd line mBC**
  - Xeloda + lapatinib
  - Kadcyla (EMILIA)

- **Neoadjuvant BC**
  - Herceptin + Perjeta + chemo (Neosphere, Tryphaena)\(^2\)

**Established standard of care**
- Potential new standard of care
- Potential future standard of care

**NEOSPHERE study filed for neoadjuvant breast cancer indication in EU**

Timelines refer to the expected dates of first filing; \(^1\) approved in JP since 2011, in EU 2012; \(^2\) approved in US since 2013
Agenda

Update on key oncology data

Breast cancer

Avastin in 1st line maintenance and treatment through multiple lines HER2-neg. mBC: phase 3 IMELDA and TANIA

Perjeta in 1st line HER2-pos. mBC: final overall survival data phase 3 CLEOPATRA

Melanoma

Cobimetinib + Zelboraf in metastatic BRAF-mutated melanoma frontline setting: phase 3 coBRIM
Safety and efficacy of cobimetinib + Zelboraf vs Zelboraf alone
cobraM study design

Published online in the New England Journal of Medicine; Larkin et al., Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma

Primary endpoint:
- Investigator-assessed progression-free survival (PFS)

Key secondary endpoints:
- Overall survival (OS)
- Independent Review Committee assessed PFS
- Objective response rate (ORR)

Stratification:
- Geographic region and extent of disease (M1c vs. other)

495 people with unresectable, previously untreated BRAFT600 mutation-positive (cobas® 4800) advanced skin cancer

RANDOMISATION

Zelboraf 960mg BID x 28 days (1-28) + Cobimetinib 60mg QD x 21 days (1-21)
Disease progression, unacceptable toxicity or withdrawal of consent

Zelboraf 960mg BID x 28 days (1-28) + placebo
**coBRIM: Cobimetinib plus Zelboraf significantly improved PFS**

<table>
<thead>
<tr>
<th></th>
<th>Vemurafenib + placebo</th>
<th>Vemurafenib + cobimetinib</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of PFS events</td>
<td>128</td>
<td>79</td>
</tr>
<tr>
<td>Median PFS, months (95% CI), by investigators</td>
<td>6.2 (2.6, 7.4)</td>
<td>9.9 (9.0, NE)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI) p value</td>
<td>0.51 (0.39, 0.68)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Median PFS, months (95% CI), IRC*-assessed</td>
<td>6.0 (5.6, 7.5)</td>
<td>11.3 (8.5, NE)</td>
</tr>
<tr>
<td>Hazard ratio (95% CI) p value</td>
<td>0.60 (0.45-0.79)</td>
<td>0.0003</td>
</tr>
</tbody>
</table>

- Cobimetinib plus Zelboraf combo: filed in Europe
- Fast-track designation in US; FDA filing expected Q4 2014

*Independent Review Facility*
**coBRIM: Overall Survival and overall response rates**

<table>
<thead>
<tr>
<th></th>
<th>Vemurafenib + placebo</th>
<th>Vemurafenib + cobimetinib</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of OS events</td>
<td>51</td>
<td>34</td>
</tr>
<tr>
<td>Median OS</td>
<td>NE</td>
<td>NE</td>
</tr>
<tr>
<td>Hazard ratio (95% CI)</td>
<td>0.65 (0.42, 1.00)</td>
<td>0.046</td>
</tr>
<tr>
<td>p value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Confirmed ORR - %* (95% CI)</td>
<td>45 (38.5, 51.2)</td>
<td>68 (61.4, 73.4)</td>
</tr>
<tr>
<td>Complete Response, n (%)</td>
<td>11 (4)</td>
<td>25 (10)</td>
</tr>
</tbody>
</table>

Cobimetinib plus Zelboraf combination regimen has a competitive ORR
**coBRIM: Overall safety summary**

*Safety profile of combination consistent with previous studies*

<table>
<thead>
<tr>
<th></th>
<th>Zelboraf + Placebo (n=239)</th>
<th>Zelboraf + Cobimetinib (n=254)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total number of patients with at least 1 adverse event (AE), n (%)</strong></td>
<td>233 (98)</td>
<td>250 (98)</td>
</tr>
<tr>
<td><strong>Total number of patients with at least 1 of the following:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grade ≥ 3 AE, n (%)</td>
<td>142 (59)</td>
<td>165 (65)</td>
</tr>
<tr>
<td>Grade 5 AE, n (%)</td>
<td>3 (1)</td>
<td>6 (2)</td>
</tr>
<tr>
<td>Serious AE, n (%)</td>
<td>60 (25)</td>
<td>75 (30)</td>
</tr>
<tr>
<td>AE leading to withdrawal of vemurafenib, n (%)</td>
<td>32 (13)</td>
<td>35 (14)</td>
</tr>
<tr>
<td>AE leading to withdrawal of cobimetinib/placebo, n (%)</td>
<td>33 (14)</td>
<td>42 (17)</td>
</tr>
<tr>
<td>AE leading to withdrawal of both cobimetinib and vemurafenib, n (%)</td>
<td>28 (12)</td>
<td>37</td>
</tr>
</tbody>
</table>
**coBRIM: Summary and conclusions**

*Combined BRAF and MEK inhibition results in improved clinical outcomes*

**Efficacy**

- The combination of cobimetinib plus Zelboraf compared to Zelboraf alone resulted in:
  - 49% reduction in risk of progression (HR = 0.51; 95% CI, 0.39 to 0.68; P<0.0001)
  - A median PFS of 9.9 months vs 6.2 months
  - The frequency of complete and partial response of 68% versus 45% (P<0.0001)
  - Interim OS showed a reduction in risk of death - *magnitude to be disclosed this afternoon*

**Safety**

- The addition of cobimetinib to Zelboraf was tolerable and consistent with the adverse event profile of the combination
  - The frequency of grade ≥ 3 AEs was 65% vs 59%
  - There was no difference in the rate of study drug discontinuation between arms
  - The frequency of secondary cutaneous neoplasms decreased

- **Strong clinical benefit supported filing**
- **Mature OS data expected 2015**
- **Metastatic melanoma treatment options are expanding rapidly**
Update on cancer immunotherapy

Cathi Ahearn, Lifecycle Leader anti-PDL1, Genentech
Cancer immunotherapy at Roche
Pipeline overview

Pre-clinical
- ImmTAC
- Neg. Regulator NME 1
- IMA 942
- Anti-cytokine NME 2
- T-cell bispecific

Phase I
- Anti-PDL1
  - Solid tumors
- Anti-PDL1+Avastin
  - Solid tumors
- Anti-PDL1+cobimetinib
  - Solid tumors
- Anti-PDL1+Zelboraf
  - Met. Melanoma
- Anti-PDL1+Tarceva
  - NSCLC
- Anti-PDL1 + immune m.
  - Solid tumors
- Anti-PDL1 + Gazyva
  - Heme tumors
- CSF1R huMAb
  - solid tumors
- CEA IL-2v
- Anti-OX40
- Anti-CD40
- INO-5150

Phase II
- Anti-PDL1
  - NSCLC (Dx+)
- Anti-PDL1
  - NSCLC
- Anti-PDL1 + Avastin
  - Renal
- Anti-PDL1 + Tarceva
  - Bladder
- CSF1R huMAb
  - PVNS

Phase III
- Anti-PDL1
  - NSCLC 2/3 L
- Anti-PDL1
  - Bladder
- Anti-PDL1
  - NSCLC 1L, Dx+

Note: Anti-PDL1 is listed as MPDL3280A in clinicaltrials.gov
MPDL3280A - The present and the future

**Monotherapy**

*Phase I results*
- mUBC
- mRCC
- Loc adv /mNSCLC

*Active clinical trials*
- mRCC (Ph II)
- mUBC (Ph II)
- Loc adv /mNSCLC (Ph II ‘BIRCH’, ‘POPLAR’, ‘FIR’, Ph III ‘OAK’)
- Solid tumours & heme (Ph I)

*Planned clinical trial*
- Ph III Dx+ 1L NSCLC
- Ph III mUBC

**Combination with chemotherapy**

*Phase Ib results*
- mCRC with Avastin + FOLFOX

*Active clinical trial*
- Loc adv /metastatic solid tumours: with Avastin +/- chemotherapy (Ph Ib)

**Immune doublets**

*Active clinical trial*
- Loc adv/ metastatic solid tumours with ipilimumab or Interferon alfa-2b (Ph I)

**Combination with targeted therapy**

*Phase I results*
- mRCC with Avastin
- mCRC with Avastin

*Active clinical trials*
- mRCC with Avastin (Ph II)
- EGFR+ NSCLC w/Tarceva (Ph Ib)
- mMel with vemurafinib (Ph Ib)
- Solid tumours with Avastin (Ph Ib)
- Solid tumors w/cobimetinib (Ph Ib)
- Lymphoma with Gazyva (Ph Ib)

- Identify patients most likely to benefit from MPDL3280A as monotherapy
- Expand depth, breadth and durability of response to extend survival with well-tolerated combinations
- Enhance understanding of immune biology to guide combination strategies

- Identify patients most likely to benefit from MPDL3280A as monotherapy
- Expand depth, breadth and durability of response to extend survival with well-tolerated combinations
- Enhance understanding of immune biology to guide combination strategies
Comprehensive approach to biomarker discovery

- Identify the right indications to test our hypotheses
- Identify patients who may best respond to our therapies
- Understand what drives resistance to develop informed combination strategies
Update on cancer immunotherapy

MPDL3280A (anti-PDL1) in solid tumors
- Metastatic renal cell carcinoma monotherapy (phase 1a) & combination with Avastin
- Combination with Avastin +/- chemo (FOLFOX) in advanced solid tumors (phase 1b)
- Clinical activity in metastatic urothelial bladder cancer (phase 1 update)
MPDL3280A Phase Ia

Phase Ia Expansion Ongoing

**Key Eligibility Criteria**

*Measurable disease per RECIST v1.1
ECOG PS 0 or 1*

- First RCC patient was enrolled on Dec 12, 2011. Last RCC patient was enrolled on Jul 18, 2013

MPDL3280A administered by IV q3w for up to 16 cycles

## Tumor Types

<table>
<thead>
<tr>
<th>RCC</th>
<th>NSCLC</th>
<th>Melanoma</th>
<th>Bladder</th>
<th>Other Tumor Types</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. All-comers</td>
<td>1. All-comers</td>
<td>All-comers</td>
<td>1. PD-L1+ patients</td>
<td>1. PD-L1+ patients</td>
</tr>
<tr>
<td>2. PD-L1+ patients</td>
<td>2. PD-L1+ patients</td>
<td></td>
<td>2. All-comers</td>
<td>2. All-comers</td>
</tr>
</tbody>
</table>
MPDL3280A: Treatment-Related Adverse Events

*Safety-evaluable population with RCC in Phase I expansion*

- Median duration of treatment was 239 days (21-834 days)
- 80% of patients experienced a treatment-related AE
- Treatment-related Grade 3 AEs occurred in 11 patients (16%), including anemia (4%), dehydration (3%), fatigue (3%) and hypophosphatemia (3%)
- No treatment-related Grade 4 AEs or deaths were reported

<table>
<thead>
<tr>
<th>Patients with RCC, N = 69 (Data cutoff Apr 21, 2014)</th>
<th>All Grade n (%)</th>
<th>Grade 3-4 n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatigue</td>
<td>15 (22%)</td>
<td>2 (3%)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>11 (16%)</td>
<td>0</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>10 (15%)</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>10 (15%)</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>8 (12%)</td>
<td>0</td>
</tr>
<tr>
<td>Pruritus</td>
<td>8 (12%)</td>
<td>0</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>8 (12%)</td>
<td>0</td>
</tr>
<tr>
<td>Chills</td>
<td>7 (10%)</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>7 (10%)</td>
<td>0</td>
</tr>
</tbody>
</table>

Includes all grade events occurring in ≥ 7 patients (10%).

*McDermott et al., 26-30 September 2014, Madrid, Spain*
MPDL3280A: Efficacy by PD-L1 IHC (IC)

Efficacy-evaluable population with clear cell RCC

<table>
<thead>
<tr>
<th>PD-L1 IHC - tumor-infiltrating immune cells (IC)(^a), n = 62</th>
<th>ORR (95% CI), %</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>15% (8-25)</td>
</tr>
<tr>
<td>IHC (IC) 1/2/3</td>
<td>20% (9-37)</td>
</tr>
<tr>
<td>IHC (IC) 0</td>
<td>10% (2-30)</td>
</tr>
</tbody>
</table>

- 24-week PFS rate was 51% (95% CI: 38-63)
- 1 CR (IHC [IC] 3)
- ORR for Fuhrman grade 4 or sarcomatoid clear cell RCC (n = 18) was 22% (95% CI: 8, 47)
- Higher response rate observed in MSKCC poor-risk patients with PD-L1 IHC 1/2/3 expression

\(^a\) A PD-L1+ cohort of patients was enrolled. 6 patients had unknown PD-L1 IHC (IC) status.

Investigator-assessed confirmed ORRs per RECIST v1.1.


IHC 3: ≥ 10% of ICs are PD-L1+; IHC 2: ≥ 5% but < 10% of ICs are PD-L1+; IHC 1: ≥ 1% but < 5% of ICs are PD-L1+; IHC 0: < 1% are PD-L1+.

McDermott et al., 26-30 September 2014, Madrid, Spain
MPDL3280A: Summary of ORR in Clear Cell RCC

**Efficacy-evaluable population with clear cell RCC in Phase I expansion**

- Median duration of follow-up was 9 months (range, 1-27 months)

Patients dosed by Oct 21, 2013; data cutoff Apr 21, 2014. Investigator-assessed confirmed ORRs per RECIST v1.1. CR, complete response; PR, partial response; PD, progressive disease; SD, stable disease; UE, unable to evaluate.

McDermott et al., 26-30 September 2014, Madrid, Spain
MPDL3280A + Bevacizumab: Phase Ib Study Design Arm A\textsuperscript{a}

- **Primary objectives**: safety, tolerability, DLT and MTD
- **Secondary objectives**: preliminary anti-tumor activity and PK

\textsuperscript{a} Lieu et al., abstract 1049O, presented Saturday.
Rationale to Combine MPDL3280A With Bevacizumab

• Single agent bevacizumab (10 mg/kg) has demonstrated a 10% ORR [95% CI: 2.9, 24.2] in RCC

• Anti-VEGF therapy has immunomodulatory properties
  – Increases trafficking of T cells into tumors
  – Reduces suppressive cytokines and infiltrating Tregs and MDSCs

MDSC, myeloid-derived suppressor cell; Tregs, regulatory T cells.

MPDL3280A + Bevacizumab: Summary of Phase Ib Results

Safety and efficacy of patients in Arm A

- Safety
  - All patients in Arm A (n = 35) experienced an AE, with 49% experiencing a G3-4 AE, regardless of attribution
  - 1 MPDL3280A-related Grade 3 AE occurred (1 case of neutropenia in Arm A)
  - No Grade 4 AEs or deaths were attributed to MPDL3280A

- Efficacy in patients with 1L clear cell RCC
  - 4 of 10 patients demonstrated an objective response
  - 5 of 10 patients experienced stable disease
  - Responding patients included 2 with IHC (IC) 1, 1 with IHC (IC) 0 and 1 with IHC (IC) unknown

![Graph showing change in sum of longest diameters from baseline over time](image)

Lieu et al., abstract 1049O, presented Saturday.
IHC 3: ≥ 10% of ICs are PD-L1+; IHC 2: ≥ 5% and < 10% of ICs are PD-L1+. IHC 1: ≥ 1% and < 5% of ICs are PD-L1+; IHC 0: < 1% ICs are PD-L1+.

McDermott et al., 26-30 September 2014, Madrid, Spain
MPDL3280A + Bevacizumab: Duration of Treatment and Response in 1L RCC

Efficacy-evaluable population with 1L clear cell RCC in Arm A

- SD ≥ 24 weeks in 4 patients
- 9 of 10 patients with mRCC remain on study treatment

---

Lieu et al., abstract 1049O, presented Saturday.

Patients dosed by Apr 7, 2014 who had at least 1 scan; data cutoff Jul 7, 2014.

IHC 3: ≥ 10% of ICs are PD-L1+; IHC 2: ≥ 5% and < 10% of ICs are PD-L1+. IHC 1: ≥ 1% and < 5% of ICs are PD-L1+; IHC 0: < 1% ICs are PD-L1+

---

McDermott et al., 26-30 September 2014, Madrid, Spain
Study WO29074 MPDL3280A: Phase II Trial in mRCC (NCT01984242)

- Key objectives: evaluate efficacy of sunitinib vs MPDL3280A as monotherapy or in combination with bevacizumab
- Primary endpoint: PFS per RECIST v1.1
- Crossover allowed

Previously untreated mRCC
N = 300

Randomized

MPDL3280A (IV)
1200 mg q3w × 8 cycles or up to 1 y (6-wk cycles)

MPDL3280A (IV)a + bevacizumab (IV)b
  a 1200 mg q3w × 8 cycles or up to 1 y (6-wk cycles)
  b 15 mg/kg q3w until PD (6-wk cycles)

Sunitinib (oral)
50 mg/day for 4 wk, 2 wk rest, until PD (6-wk cycles)
MPDL3280A in RCC: Conclusions

• MPDL3280A was well tolerated in RCC
  – Both as a single agent and in combination with bevacizumab
• MPDL3280A demonstrated promising efficacy in previously treated clear cell mRCC
  – Median PFS = 24 weeks (5-98+)
  – ORR = 22% for Fhruman grade 4 or sarcomatoid clear cell mRCC
• Preliminary data indicate that that patients with IHC 1/2/3 tumors had better efficacy vs patients with IHC 0 tumors
• MPDL3280A demonstrated clinical activity in combination with bevacizumab in 1L clear cell mRCC
  – ORR = 40%; SD = 50%
Agenda

Update on cancer immunotherapy

**MPDL3280A (anti-PDL1) in solid tumors**

Metastatic renal cell carcinoma monotherapy (phase 1a) & combination with Avastin

Combination with Avastin +/- chemo (FOLFOX) in advanced solid tumors (phase 1b)

Clinical activity in metastatic urothelial bladder cancer (phase 1 update)
Rationale to Combine MPDL3280A With Bevacizumab and FOLFOX

- Anti-VEGF therapy has immunomodulatory properties
  - Increases trafficking of T cells into tumors\(^1,2\)
  - Reduces suppressive cytokines and infiltrating Tregs and MDSCs\(^3,4\)

- FOLFOX may have immunogenic effects
  - 5-FU reduces tumor-associated MDSCs and increases CD8 tumor-infiltrating lymphocytes\(^5\)
  - Oxaliplatin induces immunogenic cell death (calreticulin exposure, release of ATP and HMGB1)\(^6,7\)

MDSC, myeloid-derived suppressor cell.


Lieu et al., 26-30 September 2014, Madrid, Spain
Phase Ib Study Design

Arm A

- **Solid tumors**
  - MPDL3280A IV q3w + Bev 15 mg/kg IV q3w
  - n = 6

Arm B

- **OX-naive CRC**
  - MPDL3280A IV q2w + Bev 10 mg/kg IV q2w + FOLFOX
  - n = 6

**Primary objectives:** safety and tolerability, DLT and MTD

**Secondary objectives:** preliminary anti-tumor activity and PK

n represent target enrollments.
Bev, bevacizumab; OX, oxaliplatin.

Lieu et al., 26-30 September 2014, Madrid, Spain
Adverse Events

- All Grade AEs attributed to MPDL3280A: Arm A 77%; Arm B 78%
- Grade 3 AEs attributed to MPDL3280A: Arm A 3%; Arm B 17%
- No Grade 4 AEs or deaths related to MPDL3280A

<table>
<thead>
<tr>
<th>AEs Regardless of Attribution</th>
<th>Arm A, n = 35</th>
<th>Arm B, n = 36</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All Grade</td>
<td>Grade 3-4</td>
</tr>
<tr>
<td>All</td>
<td>35 (100%)</td>
<td>17 (49%)</td>
</tr>
<tr>
<td>Peripheral neuropathy</td>
<td>2 (6%)</td>
<td>0</td>
</tr>
<tr>
<td>Fatigue</td>
<td>16 (46%)</td>
<td>0</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>11 (31%)</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>13 (37%)</td>
<td>0</td>
</tr>
<tr>
<td>Temperature intolerance</td>
<td>1 (3%)</td>
<td>0</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>1 (3%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>9 (26%)</td>
<td>0</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>13 (37%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>7 (20%)</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grade 3-4 AEs Regardless of Attribution</th>
<th>Arm A, n = 35</th>
<th>Arm B, n = 36</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Grade 3-4</td>
<td>Grade 3-4</td>
</tr>
<tr>
<td>All</td>
<td>17 (49%)</td>
<td>24 (67%)</td>
</tr>
<tr>
<td>Neutropenia</td>
<td>1 (3%)</td>
<td>14 (39%)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>0</td>
<td>4 (11%)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>3 (9%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>3 (9%)</td>
<td>1 (3%)</td>
</tr>
<tr>
<td>Pneumonia</td>
<td>3 (9%)</td>
<td>0</td>
</tr>
<tr>
<td>AST increased</td>
<td>0</td>
<td>3 (8%)</td>
</tr>
<tr>
<td>ALT increased</td>
<td>0</td>
<td>3 (8%)</td>
</tr>
<tr>
<td>Hyperbilirubinemia</td>
<td>2 (6%)</td>
<td>0</td>
</tr>
<tr>
<td>Tumor pain</td>
<td>2 (6%)</td>
<td>0</td>
</tr>
</tbody>
</table>
Summary of Responses

<table>
<thead>
<tr>
<th>Indication</th>
<th>n</th>
<th>ORR</th>
</tr>
</thead>
<tbody>
<tr>
<td>1L RCC</td>
<td>10</td>
<td>40%</td>
</tr>
<tr>
<td>CRC</td>
<td>13</td>
<td>8%</td>
</tr>
</tbody>
</table>

Minimum follow-up in Arm A: 2.1 months for 1L RCC and 1.9 months for CRC

Investigator-assessed unconfirmed response per RECIST v1.1.
Efficacy evaluable patients dosed by April 7, 2014, who had at least 1 scan; data cutoff, July 7, 2014.

• Responses in other cohorts
  – Arm A: melanoma (1/4 PR), breast cancer (1/1 PR)
  – Arm B: RCC (1/1 CR), breast cancer (1/2 PR)
Tumor Burden Over Time in CRC

MPDL3280A + Bevacizumab

- SD ≥ 24 weeks in 2 patients
- Median duration of follow-up: 5.6 months

MPDL3280A + Bevacizumab + FOLFOX

- SD ≥ 24 weeks in 8 patients
- Several patients had PRs as early as 6 weeks (first scan)
- Median duration of follow-up: 8.8 months

Investigator-assessed unconfirmed response per RECIST v1.1.

Does not include 2 patients: 1 patient did not have a scan post baseline and another patient had 1 target lesion that was not evaluable. IHC 3, 2, 1, 0: ≥ 10%, ≥ 5% and < 10%, ≥ 1% and < 5%, < 1% tumor-infiltrating immune cells positive for PD-L1, respectively; IHC status not available for 1 patient. Efficacy evaluable patients dosed by April 7, 2014, who had at least 1 scan; data cutoff, July 7, 2014.

Investigator-assessed unconfirmed response per RECIST v1.1. For 1 patient, the sum of longest diameters could not be computed after RECIST overall assessment of SD because one of the target lesions was un evaluable at TA2. A new lesion was also identified at this visit. IHC 3, 2, 1, 0: ≥ 10%, ≥ 5% and < 10%, ≥ 1% and < 5%, < 1% tumor-infiltrating immune cells positive for PD-L1, respectively; IHC status not available for 9 patients. Efficacy evaluable patients dosed by April 7, 2014, who had at least 1 scan; data cutoff, July 7, 2014.
Conclusions

- MPDL3280A combination therapy with bevacizumab and bevacizumab + FOLFOX was well tolerated without exacerbation of bevacizumab or chemotherapy-associated adverse events
- Responses were observed in a variety of tumor types, including RCC and CRC
- Increased PD-L1 expression or activated peripheral T cells were observed with both treatment regimens
- Additional clinical trials of MPDL3280A combination therapies are planned/ongoing
  - A Phase II trial of MPDL3280A ± bevacizumab vs sunitinib in patients with previously untreated locally advanced or metastatic RCC is currently ongoing\(^1\)
  - A randomized trial (MODUL) investigating MPDL3280A in the 1L mCRC maintenance setting is expected to start later this year\(^2\)

Agenda

Update on cancer immunotherapy

**MPDL3280A (anti-PDL1) in solid tumors**
Metastatic renal cell carcinoma monotherapy (phase 1a) & combination with Avastin

Combination with Avastin +/- chemo (FOLFOX) in advanced solid tumors (phase 1b)

Clinical activity in metastatic urothelial bladder cancer (phase 1 update)
**MPDL3280A Phase Ia**

**Phase Ia Expansion Ongoing**

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Eligibility Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>RCC</td>
<td>1. All-comers 2. PD-L1+ patients</td>
</tr>
<tr>
<td>Melanoma</td>
<td>All-comers</td>
</tr>
<tr>
<td>NSCLC</td>
<td>1. All-comers 2. PD-L1+ patients</td>
</tr>
<tr>
<td>Other Tumor Types</td>
<td>1. PD-L1+ patients 2. All-comers</td>
</tr>
<tr>
<td>UBC (15 mg/kg)</td>
<td>1. PD-L1+ patients 2. All-comers</td>
</tr>
</tbody>
</table>

MPDL3280A administered by IV q3w for up to 16 cycles

**Key Eligibility Criteria**

*Measurable disease per RECIST v1.1*

*ECOG PS 0 or 1*

---

*Primarily recruited PD-L1—negative patients.*

Bellmunt J et al., 26-30 September 2014, Madrid, Spain
MPDL3280A: Treatment-Related AEs

Safety-evaluable population with UBC in Phase I expansion

<table>
<thead>
<tr>
<th>Patients With UBC N = 74</th>
<th>All Grade n (%)</th>
<th>Grade 3-4(^a) n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>All</td>
<td>48 (65%)</td>
<td>4 (5%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>11 (15%)</td>
<td>0</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>9 (12%)</td>
<td>0</td>
</tr>
<tr>
<td>Nausea</td>
<td>8 (11%)</td>
<td>0</td>
</tr>
<tr>
<td>Pruritus</td>
<td>7 (9%)</td>
<td>0</td>
</tr>
<tr>
<td>Pyrexia</td>
<td>7 (9%)</td>
<td>0</td>
</tr>
<tr>
<td>Asthenia</td>
<td>5 (7%)</td>
<td>1 (1%)</td>
</tr>
<tr>
<td>Chills</td>
<td>3 (4%)</td>
<td>0</td>
</tr>
<tr>
<td>Dry skin</td>
<td>3 (4%)</td>
<td>0</td>
</tr>
<tr>
<td>Influenza-like illness</td>
<td>3 (4%)</td>
<td>0</td>
</tr>
<tr>
<td>Lethargy</td>
<td>3 (4%)</td>
<td>0</td>
</tr>
<tr>
<td>Rash</td>
<td>3 (4%)</td>
<td>0</td>
</tr>
</tbody>
</table>

- Median treatment duration 95 days (5.5 cycles)
- MPDL3280A well tolerated in patients with UBC
  - No discontinuations due to treatment-related AEs
  - No investigator-assessed immune-related toxicities reported as of the clinical cutoff
- MPDL3280A not observed to be associated with renal toxicity
- No treatment-related grade 5 AEs

\(^a\) Additional treatment-related grade 3/4 AEs: One patient experienced an increase in alanine aminotransferase (grade 3), aspartate aminotransferase (grade 3) and gamma-glutamyltransferase (grade 4). Two additional patients (one each) experienced either thrombocytopenia (grade 3) or decreased blood phosphorus (grade 3). Clinical data cutoff was April 21, 2014. Includes events occurring in ≥ 3 patients.
MPDL3280A: Summary of ORR in UBC

**Efficacy-evaluable population with UBC in Phase I expansion**

<table>
<thead>
<tr>
<th>PD-L1 IHC (IC)</th>
<th>ORR, Best Response % (95% CI)</th>
<th>PD-L1+ vs PD-L1− ORR, Best Response % (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHC 3 (n = 10)</td>
<td>60% (27, 85)</td>
<td></td>
</tr>
<tr>
<td>IHC 2 (n = 23)</td>
<td>48% (27, 68)</td>
<td>52% (34, 69)</td>
</tr>
<tr>
<td>IHC 1 (n = 24)</td>
<td>17% (6, 37)</td>
<td>14% (6, 28)</td>
</tr>
<tr>
<td>IHC 0 (n = 12)</td>
<td>8% (0, 35)</td>
<td></td>
</tr>
</tbody>
</table>

- 3 CRs (1 IHC 2, 2 IHC 3)
- Median follow-up was 6 months (range, 1+ to 12) for PD-L1+ patients and 4 months (range, 1+ to 7) for PD-L1− patients

Investigator-assessed ORRs (unconfirmed) per RECIST v1.1.
1 patient with unknown IHC status not included in table.
PD-L1+: IHC (IC) 2/3; PD-L1−: IHC (IC) 0/1.
Patients dosed by Jan 27, 2014 (≥ 12-wk follow-up) with measurable disease at baseline. Clinical data cutoff was Apr 21, 2014.

Bellmunt J et al., 26-30 September 2014, Madrid, Spain
MPDL3280A: Summary of ORR in UBC

Efficacy-evaluable population with UBC in Phase I expansion

Patients with complete responses. Patients with a CR had < 100% reduction of the target lesions due to lymph node target lesions. All lymph nodes returned to normal size per RECIST v1.1.

IC; tumor-infiltrating immune cells.

Responses are investigator assessed (unconfirmed). 7 patients are not included due to no post-baseline tumor assessments.

PD-L1+: IHC (IC) 2/3; PD-L1−: IHC (IC) 0/1.

Patients dosed by Jan 27, 2014 (≥ 12-wk follow-up) with measurable disease at baseline. Clinical data cutoff was Apr 21, 2014.

Bellmunt J et al., 26-30 September 2014, Madrid, Spain
MPDL3280A: Duration on Study, Treatment and Response in Responding Patients

Efficacy-evaluable population with UBC in Phase I expansion

- 19 of 22 responding patients had ongoing responses at the time of data cutoff
- Median duration of response has not yet been reached
  - PD-L1+ patients (n = 17): range, 0.1+ to 42+ weeks
  - PD-L1− patients (n = 5): range, 6+ to 19+ weeks

* IHC 3, 2, 1, 0: ≥ 10%, < 10% and ≥ 5%, < 5% and ≥ 1% and < 1% tumor-infiltrating immune cells positive for PD-L1, respectively.
Investigator-assessed ORRs (unconfirmed) per RECIST v1.1. Arrow indicates the status of no PD or no death only and has no implication on the timing.
Patients dosed by Jan 27, 2014 (≥ 12-wk follow-up) with measurable disease at baseline. Clinical data cutoff was Apr 21, 2014.
MPDL3280A: Summary of Progression Free Survival

Efficacy-evaluable population with UBC in Phase I expansion

<table>
<thead>
<tr>
<th>PD-L1 IHC (IC)</th>
<th>Median PFS (range), weeks</th>
<th>PD-L1+ vs PD-L1– Median PFS (range), weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>IHC 3 (n = 10)</td>
<td>Not reached (5 to 48+)</td>
<td>24 (5 to 50+)</td>
</tr>
<tr>
<td>IHC 2 (n = 23)</td>
<td>24 (5 to 50+)</td>
<td></td>
</tr>
<tr>
<td>IHC 1 (n = 24)</td>
<td>11 (0.1+ to 30+)</td>
<td>8 (0.1+ to 30+)</td>
</tr>
<tr>
<td>IHC 0 (n = 12)</td>
<td>7 (5 to 24+)</td>
<td></td>
</tr>
</tbody>
</table>

- Median PFS appears to be associated with PD-L1 expression

Investigator-assessed PFS per RECIST v1.1.
PD-L1+: IHC (IC) 2/3; PD-L1–: IHC (IC) 0/1.
Patients dosed by Jan 27, 2014 (≥ 12-wk follow-up) with measurable disease at baseline. Clinical data cutoff was Apr 21, 2014.

Bellmunt J et al., 26-30 September 2014, Madrid, Spain
Study GO29293 MPDL3280A: Phase II Trial in mUBC (NCT02108652)

Locally advanced or met urothelial bladder cancer
N = 330

MPDL3280A
1200 mg q3w × 8 cycles or up to 1 y (6-wk cycles)

Key objectives: ORR, DoR, PFS per RECIST v1.1, OS, safety

- 2 cohorts recruiting
  - cohort 1: treatment naive and cisplatin-ineligible, N=30
  - cohort 2: 2nd line patients who progressed on platinum-containing treatment, N=300
MPDL3280A: Conclusions in UBC

- MPDL3280A had high ORR of 52% observed in mostly platinum-pretreated IHC 2/3 patients with metastatic UBC
  - ORR of 14% observed in IHC 0/1 patients
  - Rapid responses seen
  - 19 of 22 responding patients had ongoing responses at the time of data cutoff
  - Median PFS was 24 weeks in IHC 2/3 patients and 8 weeks in IHC 0/1 patients
- MPDL3280A was well tolerated
  - Only 5% of patients experienced Grade 3/4 treatment-related AEs
  - There were no grade 5 treatment-related AEs
  - Renal toxicity has not been observed in MPDL3280A-treated patients to date
- On-treatment plasma tumor burden markers, but not baseline markers, associated with response
- Additional studies of MPDL3280A in UBC are planned and ongoing (including NCT02108652)
Roche ESMO 2014: Summary

- **Colorectal cancer:**
  - Avastin, the only drug with proven survival benefit in 1\textsuperscript{st} and 2\textsuperscript{nd} line, and across multiple lines (TML), irrespective of biomarker status

- **Breast cancer:**
  - Perjeta unprecedented overall survival benefit in Her2-positive breast cancer
  - Avastin: continued commitment to improving outcomes for people with HER2-negative metastatic breast cancer

- **Melanoma:**
  - Cobimetinib plus Zelboraf offers strong profile in a market with rapidly changing treatment options

- **Cancer immunotherapy (aPDL1):** Committed to making a difference
  - Bladder cancer: strong set of data in monotherapy
  - Renal cancer: early promising efficacy in mono and in combo with Avastin
  - CRC: good safety profile in combination with Avastin and chemo backbone
Doing now what patients need next